News and Events

Combination therapy for non-small cell lung cancer studied in new clinical trial

Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is slow growing and can affect smokers and non-smokers alike. David S. Schrump, M.D., Surgical Chief of the Thoracic and Gastrointestinal Oncology Branch, is leading the NCI’s participation in a multicenter trial of a combination drug therapy in patients with NSCLC. Read more...

Yves Pommier named fellow of the American Association for the Advancement of Science

Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch, was recently elected a fellow of the American Association for the Advancement of Science (AAAS). Election as a fellow honors AAAS members whose efforts to advance science or its applications have distinguished them among their peers and colleagues. The 2017 AAAS Fellows will be recognized on Feb. 17, 2018 at the AAAS annual meeting in Austin, TX. Read more...

Michael Gottesman honored with Order of the Rising Sun by Japanese Government

The Government of Japan recently honored Michael Gottesman, M.D., Chief of the Laboratory of Cell Biology, with the Order of the Rising Sun, Gold Rays and Neck Ribbon, for his contributions toward promoting research exchange in the biomedical field between the U.S. and Japan. The Order of the Rising Sun was established in 1875 as the first national decoration awarded by the Japanese government. Read more...

New NCI video showcases one patient’s clinical-trial journey

Sue Scott was diagnosed with cervical cancer in 2011. When standard treatment failed to eliminate her cancer cells, Scott’s doctor referred her to an immunotherapy clinical trial at the National Cancer Institute (NCI) with Christian Hinrichs, M.D., Investigator and Lasker Scholar in CCR’s Experimental Transplantation and Immunology Branch. Immunotherapy is a type of cancer treatment where the patient’s own immune system is used to fight the cancer. In this video, Sue details her story of survival and experience of taking part in a clinical trial with CCR. Watch the video here.

Natalie Porat-Shliom joins CCR as NIH Stadtman Investigator

Natalie Porat-Shliom, Ph.D. has joined the Thoracic and Gastrointestinal Oncology Branch (TGIB) as a Stadtman Tenure Track Investigator. Dr. Porat-Shliom's research focuses on utilizing intravital microscopy for imaging and understanding the biology of human cancer. She will explore how normal and malignant cells metabolically adapt to changes in nutrient supply and energy demand and will address specific questions concerning metabolic heterogeneity under physiological conditions and metastatic disease using both mouse model and human samples. Learn more...

NBC4 interviews Foregut Team stomach-removal patient

The CDH1 gene mutation elevates an individual’s lifetime risk of developing stomach cancer to 60-70 percent. Total gastrectomy, or complete removal of the stomach, is a preventive option for persons with this anomaly. After receiving a positive result for the gene mutation at age 40, David Fogel began researching his options and decided to enroll in a clinical trial at the National Institutes of Health led by Jeremy Davis, M.D., Staff Clinician in the Thoracic and Gastrointestinal Oncology Branch. As part of the trial, which aims to study the effects of stomach removal for patients with the CDH1 gene mutation, Fogel had his stomach removed in October 2017. In a recent interview with Washington’s NBC4, Fogel discussed life without a stomach with a fellow Maryland resident who also underwent a total gastrectomy after testing positive for the CDH1 mutation. Watch the video here.

Foregut team stomach-removal patient featured in The Washington Post

Individuals with the CDH1 gene mutation have an increased risk of developing stomach cancer. Over the last two decades, total gastrectomy, or removal of the stomach, has become an extreme preventive option for those with the CDH1 mutation. After testing positive for the mutation at age 40, David Fogel began researching his options and decided to enroll in a clinical trial at the National Institutes of Health led by Jeremy Davis, M.D., Staff Clinician in the Thoracic and Gastrointestinal Oncology Branch. As part of the trial, which aims to study the effects of stomach removal for patients with the CDH1 gene mutation, Fogel had his stomach completely removed in October 2017. Now months later, Fogel is in high spirits and has no regrets. Read the full story here.

Breadcrumb